figshare
Browse
ccr-23-2142_supplementary_methods_1_suppsm1.pdf (400.91 kB)

Supplementary Methods 1 from Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System

Download (400.91 kB)
journal contribution
posted on 2024-01-05, 08:21 authored by Cenkai Shen, Xiao Shi, Duo Wen, Yuqing Zhang, Yuxin Du, Yu Zhang, Ben Ma, Haitao Tang, Min Yin, Naisi Huang, Tian Liao, Ting-Ting Zhang, Chang’e Kong, Wenjun Wei, Qinghai Ji, Yu Wang

Supplementary Methods

Funding

National Natural Science Foundation of China (NSFC)

Science and Technology Commission of Shanghai Municipality (STCSM)

Shanghai Anti-Cancer Association (上海市抗癌协会)

Shanghai Municipal Health Commission (上海市卫生健康委员会)

History

ARTICLE ABSTRACT

Medullary thyroid carcinoma (MTC) presents a distinct biological context from other thyroid cancers due to its specific cellular origin. This heterogeneous and rare tumor has a high prevalence of advanced diseases, making it crucial to address the limited therapeutic options and enhance complex clinical management. Given the high clinical accessibility of methylation information, we construct the largest MTC methylation cohort to date. Seventy-eight fresh-frozen MTC samples constituted our methylation cohort. The comprehensive study process incorporated machine learning, statistical analysis, and in vitro experiments. Our study pioneered the identification of a three-class clustering system for risk stratification, exhibiting pronounced epigenomic heterogeneity. The elevated overall methylation status in MTC-B, combined with the “mutual exclusivity” of hypomethylated sites displayed by MTC-A and MTC-C, distinctively characterized the MTC-specific methylation pattern. Integrating with the transcriptome, we further depicted the features of these three clusters to scrutinize biological properties. Several MTC-specific aberrant DNA methylation events were emphasized in our study. NNAT expression was found to be notably reduced in poor-prognostic MTC-C, with its promoter region overlapping with an upregulated differentially methylated region. In vitro experiments further affirmed NNAT's therapeutic potential. Moreover, we built an elastic-net logistic regression model with a relatively high AUC encompassing 68 probes, intended for future validation and systematic clinical application. Conducting research on diseases with low incidence poses significant challenges, and we provide a robust resource and comprehensive research framework to assist in ongoing MTC case inclusion and facilitate in-depth dissection of its molecular biological features.